Abstract:Resistance to breast cancer (BCa) chemotherapy severely hampers the patient's prognosis. MicroRNAs provide a potential therapeutic prospect for BCa. In this study, the reversal function of microRNA34a (miR34a) on doxorubicin (Dox) resistance of BCa and the possible mechanism was investigated. We found that the relative level of miR34a was significantly decreased in Dox-resistant breast cancer cell MCF-7 (MCF-7/A) compared with Dox-sensitive MCF-7 cells. Transfection with miR34a significantly suppressed the invasion, migration, adhesion of MCF-7/A cells without inhibiting their growth obviously. The combination of miR34a and Dox could significantly inhibit the proliferation, migration, invasion and induce the apoptosis of MCF-7/A cells. The synergistic effect of this combination on resistant MCF-7/A cells has no obvious relation with the expressions of classical drug-resistant proteins P-GP, MRP and GST-π, while closely related with the down-regulation on TOP2A and BCRP. Moreover, we found both protein and mRNA expression of Snail were significantly up-regulated in MCF-7/A cells in comparison with MCF-7 cells. Transfection with small interfering RNA (siRNA) of Snail could inhibit the invasion, migration and adhesion of drug-resistant MCF-7/A cells, while high-expression of Snail could remarkably promote the invasion, migration and adhesion of MCF-7 cells, which might be related with regulation of N-cadherin and E-cadherin. Transfection with miR34a in MCF-7/A cells induced a decrease of Snail expression. The potential binding sites of miR34a with 3' UTR of Snail were predicted by miRDB target prediction software, which was confirmed by luciferase reporter gene method. Results showed that the relative activity of luciferase was reduced in MCF-7/A cells after co-transfection of miR34a and wild type (wt)-Snail, while did not change by co-transfection with miR34a and 3' UTR mutant type (mut) Snail. Combination of miR34a and Dox induced a stronger decrease of Snail in MCF-7/A cells in comparison to miR34a or Dox treatment alone. What' more, for the first time, we also found miR34a combined with Dox could obviously inhibit the expression of Snail through suppressing Notch/NF-κB and RAS/RAF/MEK/ERK pathway in MCF-7/A cells. In vivo study indicated that combination of miR34a and Dox significantly slowed down tumor growth in MCF-7/A nude mouse xenograft model compared with Dox alone, which was manifested by the down-regulation of Snail and pro-apoptosis effect in tumor xenografts. These results together underline the relevance of miR34a-driven regulation of Snail in drug resistance and co-administration of miR34a and Dox may produce an effective therapy outcome in the future in clinic.

MiR-181 a Enhances Drug Sensitivity in Mitoxantone-Resistant Breast Cancer Cells by Targeting Breast Cancer Resistance Protein ( BCRP / ABCG 2 )

MiR-23a Modulates X-linked Inhibitor of Apoptosis-Mediated Autophagy in Human Luminal Breast Cancer Cell Lines.

Decreased NMIIA heavy chain phosphorylation at S1943 promotes mitoxantrone resistance by upregulating BCRP and N-cadherin expression in breast cancer cells

Mir-181b Modulates Multidrug Resistance By Targeting Bcl2 In Human Cancer Cell Lines

Mir-200Bc/429 Cluster Modulates Multidrug Resistance of Human Cancer Cell Lines by Targeting BCL2 and XIAP.

Mir-1915 Inhibits Bcl-2 to Modulate Multidrug Resistance by Increasing Drug-Sensitivity in Human Colorectal Carcinoma Cells.

miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1.

MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1)

MiR-181a Confers Resistance of Cervical Cancer to Radiation Therapy Through Targeting the Pro-Apoptotic PRKCD Gene

Mir-15b and Mir-16 Modulate Multidrug Resistance by Targeting Bcl2 in Human Gastric Cancer Cells

MicroRNA-181a Enhances the Chemoresistance of Human Cervical Squamous Cell Carcinoma to Cisplatin by Targeting PRKCD.

Role Of Microrna Mir-27a And Mir-451 In The Regulation Of Mdr1/P-Glycoprotein Expression In Human Cancer Cells

Combination therapy with miR34a and doxorubicin synergistically inhibits Dox-resistant breast cancer progression via down-regulation of Snail through suppressing Notch/NF- κ B and RAS/RAF/MEK/ERK signaling pathway

miR-199b-3p contributes to acquired resistance to cetuximab in colorectal cancer by targeting CRIM1 via Wnt/β-catenin signaling

miR-27a regulates the sensitivity of breast cancer cells to cisplatin treatment via BAK-SMAC/DIABLO-XIAP axis

Changes in the Expression of Mir-381 and Mir-495 Are Inversely Associated with the Expression of the MDR1 Gene and Development of Multi-Drug Resistance

miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2

Mir-122 Targets X-Linked Inhibitor of Apoptosis Protein to Sensitize Oxaliplatin-Resistant Colorectal Cancer Cells to Oxaliplatin-Mediated Cytotoxicity

Induction of Mirna-181A by Genotoxic Treatments Promotes Chemotherapeutic Resistance and Metastasis in Breast Cancer.

Exosomes regulate doxorubicin resistance in breast cancer via miR-34a-5p/NOTCH1

Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance